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Melanoma in organ transplant recipients: clinicopathological
features and outcome in 100 cases
Abstract
Organ transplant recipients have a higher incidence of melanoma compared to the general population
but the prognosis of this potentially fatal skin cancer in this group of patients has not yet been
established. To address this, we undertook a multicenter retrospective analysis to assess outcome for 100
melanomas (91 posttransplant and 9 pretransplant) in 95 individuals. Data were collected in 14 specialist
transplant dermatology clinics across Europe belonging to the Skin Care in Organ Transplant Patients,
Europe (SCOPE) Network, and compared with age, sex, tumor thickness and ulceration status-matched
controls from the American Joint Committee on Cancer (AJCC) melanoma database. Outcome for
posttransplant melanoma was similar to that of the general population for T1 and T2 tumors (< or = 2
mm thickness); but was significantly worse for T3 and T4 tumors (> 2 mm thickness); all nine
individuals with a pretransplant melanoma survived without disease recurrence following organ
transplantation. These data have implications for both cutaneous surveillance in organ transplant
recipients and management of transplant-associated melanoma.
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Abstract 
 
Organ transplant recipients have a higher incidence of melanoma compared to the general 
population but the prognosis of this potentially fatal skin cancer in this group of patients has 
not yet been established. To address this we undertook a multicentre retrospective analysis 
to assess outcome for 100 melanomas (91 post-transplant and 9 pre-transplant) in 95 
individuals. Data were collected in 14 specialist transplant dermatology clinics across Europe 
belonging to the Skin Care in Organ Transplant Patients, Europe (SCOPE) Network, and 
compared with age, sex, tumour thickness and ulceration status-matched controls from the 
American Joint Committee on Cancer (AJCC) melanoma database. All 9 individuals with a 
pre-transplant melanoma survived without disease recurrence following organ 
transplantation, suggesting that a history of melanoma should not necessarily preclude 
subsequent organ transplantation. Outcome for post-transplant melanoma was similar to that 
of the general population for T1 and T2 tumours (≤2mm thickness); but was significantly 
worse for T3 and T4 tumours (>2mm thickness). These data have implications for both 
cutaneous surveillance in organ transplant recipients and management of transplant-
associated melanoma.   
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Introduction 
 
Melanoma is an aggressive cutaneous malignancy accounting for just 4% of skin cancers 
but resulting in 80% of all skin-cancer related deaths (1). Its incidence in the general 
population is rising rapidly with estimated rates likely to treble over the next 30 years (2). An 
increased incidence of skin malignancies following organ transplantation is well established, 
in particular for keratinocyte skin cancer (squamous and basal cell carcinomas) where the 
excess risk is in the order of 50-100 fold (3, 4). Evidence also suggests an increased relative 
risk of melanoma in organ transplant recipients (OTRs), but information on outcome is 
scarce.  
 
Melanoma arises in three main clinical settings in relation to solid organ transplantation; 
donor-derived melanoma, melanoma preceding solid organ transplantation and de novo 
melanoma following solid organ transplantation. Melanoma acquired from the transplanted 
organ accounts for 28% of cases of transplanted tumours (5) making this the most common 
type of transplanted metastatic disease in OTRs. It has a very high mortality rate, with a 
reported 5-year survival of 5% (5-10). Only one study has previously addressed outcome in 
organ transplant recipients with a pre-existing melanoma and the limited data similarly 
suggest a poor prognosis (5). De novo melanoma following solid organ transplantation is the 
most common clinical scenario, with an excess relative risk attributable to transplantation of 
up to 12 in several studies (11-19). Immunological factors are implicated in both 
development and progression of melanoma (18-20), thus, in OTRs a worse prognosis might 
be anticipated although, to date, no study has had the power to address this issue.  
 
In the current study we determine prognosis for melanoma in transplant recipients compared 
with the general population using American Joint Committee on Cancer (AJCC) staging 
criteria (21), and also examine outcomes for OTRs with a history of melanoma prior to 
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transplantation. A multi-centred European collaborative study was coordinated for this 
purpose involving a network of clinicians within Skin Care in Organ Transplant Patients, 
Europe (SCOPE). The study comprises 14 cohorts of OTRs under routine surveillance in 
dedicated transplant dermatology clinics across Europe.   
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Methods 
 
Data collection from organ transplant recipient cohorts: Retrospective clinical and 
histological data were collected from 14 centres with dedicated transplant skin clinics; 
Vienna (Austria), Brussels (Belgium), Lyon, Paris (France), Berlin (Germany), Zurich 
(Switzerland), Dublin (Eire), Padova (Italy), Leiden (Netherlands), Barcelona (Spain), Ankara 
(Turkey), London, Manchester and Oxford (United Kingdom). Standard questionnaires were 
agreed by all collaborators (see supplementary material) and were completed between May 
2006 and May 2007 for all OTRs with pre- and/or post-transplant melanoma.  
Questionnaires were completed from case-notes and/or electronic patient data and 
histopathological review. 
 
Baseline demographic features including date of transplantation and date of melanoma 
diagnosis were recorded. A detailed clinical history of number of moles, presence or 
absence of atypical moles, family history of melanoma and previous history of melanoma or 
non-melanoma skin cancer was obtained. Skin type (according to the Fitzpatrick standard 
criteria) and sun exposure history were documented where available. Details of the 
melanoma were collected including site, pre-existing naevus, histological subtype (superficial 
spreading melanoma (SSM), nodular melanoma (NMM), melanoma in situ (TIS), lentigo 
maligna melanoma (LMM), other), Breslow thickness (in millimetres), Clarks Level (I-V), 
presence or absence of ulceration and regression. The sentinel lymph node status and 
AJCC staging were recorded where available. Primary tumours were classified according to 
the categories used in the TNM classification (22) – T1 – melanomas ≤1mm thickness; T2 – 
melanomas 1.01 to 2mm; T3 – melanomas 2.01-4mm and T4 – greater than 4mm. Details of 
the organ transplanted and the immunosuppressive medication at time of melanoma 
diagnosis were documented. Management, including details of any alteration of 
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immunosuppression, was noted and data on tumour recurrence, metastases and final 
outcome were collected.  
 
Comparison with the AJCC database: Each post-transplant OTR melanoma was 1:4 
matched for age, sex, Breslow thickness and ulceration with data on non-transplanted 
individuals held in the AJCC database (21). The AJCC melanoma database includes 
information on 17,600 patients with melanoma collected from 13 cancer institutes. The year 
range of melanoma diagnosis of the AJCC data was 1941-1999. AJCC data with a 
melanoma diagnosis year after 1990 (n=9,097) were included. The patients with TIS (n=23, 
27.7%) in the SCOPE data were excluded from comparison analyses because the newly 
defined AJCC dataset had few patients with TIS (n = 6, 0.07%). In total, there were 53 
patients in the SCOPE data with melanomas of stage T1 – 4 with complete records for the 
four matching factors and 212 historical controlled patients from the AJCC dataset.  
 
Statistical analysis: Tabulations and descriptive statistics were used to display results for 
pre- and post-transplant individuals as well as to show initial comparisons for subgroups and 
matched analyses. Basic comparisons (including the difference in risk of SCCs and BCCs in 
SCOPE patients compared with immunocompetent patients) were made with the chi-square 
and Fisher’s exact test as appropriate. For comparison of SCOPE individuals and subjects 
from the AJCC dataset, the main outcome was death from melanoma. Duration of follow-up 
was calculated from the date of the first organ transplanted to date of death or last known 
follow-up. Duration of immunosuppression was calculated from the date of the first transplant 
to the date of melanoma diagnosis. All individuals with a melanoma prior to transplant were 
excluded from this analysis. Results are displayed as Kaplan-Meier graphs and p-values 
comparing groups are taken from the log rank test for each categorised Breslow group. 
Statistical analyses were performed using SAS version 9.0 software (SAS Institute). 
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Results 
 
Tumours and patients:  
Between May 2006 and May 2007, data from 89 post-transplant cutaneous melanomas in 85 
patients and 8 pre-transplant cutaneous melanomas diagnosed over 31 years between 1976 
and March 2007 were collected from 14 SCOPE centres across Europe (Table 1). One 
patient (Oxford, UK) had four post-transplant melanomas (three diagnosed at the same time 
and a further one diagnosed 3 years later) and another had two diagnosed 3 years apart 
(Oxford, UK). One patient had both a pre- and a post-transplant melanoma (Lyon, France). 
In addition, three ocular melanomas were reported, one pre-transplant (Leiden, Netherlands) 
and two post-transplant (London, UK; Leiden, Netherlands). There were no reported cases 
of melanoma from the SCOPE transplant cohort in Ankara, Turkey.  
 
Clinical characteristics of post-transplant cutaneous melanoma group:  
Demographic and clinical characteristics of the post-transplant melanoma group are 
summarised in table 2. There were 89 post-transplant cutaneous melanomas in 59 males 
and 26 females. The mean age at transplantation was 45.3yrs (range 3.0 – 75.1 yrs). The 
mean age at diagnosis of melanoma was 54.0yrs (range 25.5 – 77.3yrs). The mean interval 
between first transplant and development of melanoma was 8.7yrs (range 0.1 – 24.9yrs). All 
patients transplanted more than once (n=17) were renal transplant recipients.  
 
Skin phototypes were available in 76/85 (89.4%) post-transplant individuals. Of these, 94.7% 
were skin types I-III. Only 1/68 (1.5%) individuals who reported, had a family history of 
melanoma and this individual had three melanomas diagnosed at 4.3 years and a further 
one 7.3yrs post-transplant. 24/84 (28.5%) OTRs reported a history of squamous cell 
carcinoma (SCC) with a total of 113 tumours post-transplant. 22/84 (26.2%) OTRs reported 
a history of basal cell carcinoma (BCC) with a total of 73 tumours post-transplant. This gave 
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an SCC:BCC ratio of 1.5:1. When comparing the prevalence of BCC and SCC in the SCOPE 
melanoma cohort with a London transplant population who had not developed melanoma 
(adjusted for age at transplant, sex, length of follow up and skin type), logistic regression 
showed a significant difference in the presence of BCCs or SCCs (p<0.001 for both BCC 
and SCC; OR for BCC 3.8 [95% CI; 2.0 – 7.3]; OR for SCC 4.2 [95% CI; 2.2-8.2]). This 
significant difference was also found when comparing the absolute numbers of tumours 
(p=0.01 and 0.089 for BCC and SCC respectively). One patient (London, UK) also had co-
existing Kaposi sarcoma.  
 
Thirty-eight percent of individuals reported melanoma developing from a pre-existing naevus 
and 37% of patients reported the presence of atypical melanocytic naevi. Anatomical site of 
post-transplant melanoma according to histological subtype and gender is shown in table 3. 
There was no statistical difference in predilection for each individual site (head and neck, 
trunk, upper limb or lower limb) between males and females in the transplant population (p 
values 0.322, 0.322, 0.089 and 0.221 respectively). 
 
Histopathological characteristics of post-transplant cutaneous melanoma:  
Histological data are shown in table 4 and were available for 81/89 (91%) melanomas. 
Twenty-three (28%) tumours were TIS. Of the 56 invasive subtypes, superficial spreading 
melanoma (SSM) was the most common, occurring in 71% (40/56). In two cases the primary 
tumour was unknown and the patient presented with metastatic disease. Breslow thickness 
was available in 83/89 (93%) cases. Overall, mean thickness was 1.10mm (range 0-13mm) 
and for the invasive lesions only, was 1.51 mm (0.25 – 13mm). In 73% of tumours thickness 
was less than 1mm. Analysis of thickness against date of melanoma diagnosis revealed no 
change between 1986 and 2007 (p=0.811; data not shown). A scatter plot of interval time 
between transplant and melanoma diagnosis versus thickness revealed that the duration of 
transplantation did not significantly influence thickness of post-transplant melanoma 
(p=0.069, data not shown) 
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Post-transplant cutaneous melanoma prognosis:  
Overall mortality in the post-transplant cutaneous melanoma cohort, from all causes was 
27% (24/85).  Melanoma-specific mortality was 13% (11/85). This group comprised four 
females and seven males. Breslow thickness was available for 8/11 of these cases. The 
mean tumour thickness in patients with melanoma-specific mortality was 4.4mm (range 0.34 
– 13mm), but in two cases was less than 1mm. Of those cases where tumour thickness was 
not available, one case was diagnosed in 1976 when thickness was not routinely reported 
and the other two cases presented with metastatic disease from an unknown primary. The 
mean age at transplant of those who died from melanoma was 41.3 yrs (range 25.3 – 
54.9yrs) and the mean age of diagnosis of melanoma was 50.1 yrs (range 29.1 – 64.4yrs). 
The mean interval between transplant and melanoma was 8.9 yrs (range 1.0 – 21.3yrs) and 
mean time from melanoma diagnosis to death was 22.5 months (range 2.4 – 67.2 months).  
 
Sufficient information was available in 53/85 SCOPE cohort individuals for comparison of 
outcomes when matched by age, sex, Breslow thickness and ulceration status of melanoma 
with 212 individuals from the AJCC control group (21). Details are given in table 5. Overall 
survival rates in the SCOPE cohort were 86.2%, 77.6% and 72.4% at 2, 5 and 10 years 
respectively compared to 95.6%, 82.1% and 75.2% for the AJCC control group (overall log 
rank test p value 0.5243). Outcome for SCOPE T1 and T2 melanomas separately compared 
with corresponding AJCC control groups was not significantly different (p=0.448 and 
p=0.7237 respectively). For combined stage T1 and T2 post-transplant melanomas there 
was no difference in outcome when compared to the AJCC population (p=0.4432; figure 1). 
However, a large difference in survival was detected between the SCOPE cohort and the 
AJCC group for stage T3 (p=0.4755). Prognosis was significantly worse for post-transplant 
melanomas stage T4 (p=0.0009) and outcome for combined T3 and T4 melanomas was 
also significantly worse (p=0.0169, figure 2).  
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Pre-transplant melanoma prognosis:  
Table 6 details the nine pre-transplant melanoma cases (8 cutaneous and one ocular) 
comprising two males and seven females. The mean age of melanoma diagnosis was 
44.9yrs (range 25.2 – 63.6yrs). The median interval between diagnosis and transplant was 
7.8yrs (range 0.4 - 32.5yrs). Three melanomas were stage T1 at diagnosis. The mean post 
transplant follow-up was 5yrs (range 0.5 – 10.2yrs). There were no melanoma-related 
deaths in this group. The patient with a pre-transplant ocular melanoma was also alive 
beyond 7 years post-transplant (see below). 
 
Management:  
Surgery and radiotherapy: In all cases of post-transplant primary cutaneous melanoma, 
initial treatment was with surgical wide local excision. One patient underwent additional post-
operative radiotherapy to lymph nodes (Oxford, 4.5mm). Four cases of local recurrence were 
reported at a mean of 1.6yrs (range 0.3 – 5.1yrs) post-operatively. In two cases the primary 
tumour was TIS. In the other two the thicknesses were 0.4 and 0.34mm (T1). All 4 cases 
were treated with further surgical excision and two went on to develop distant metastases. 
There were fourteen (16%) cases of locoregional and/or distant metastatic disease 
(supplementary table 1); the mean time to presentation of first metastasis was 1.02yrs (0 – 
5.01yrs). Five cases initially presented with concurrent metastases, and in two cases there 
was no evidence of a primary tumour. One patient (Lyon, France) was diagnosed with 
metastatic melanoma after returning to dialysis 17 months after stopping 
immunosuppressive therapy.     
 
Sentinel lymph node biopsy was performed in 10 cases and was positive for micrometastatic 
disease in three (30%) patients with primary tumour Breslow thicknesses of 0.34mm, 7.5mm 
and 13mm respectively. All 3 individuals subsequently died from melanoma. The remaining 
seven (70%) sentinel node negative cases had a mean tumour thickness of 1.6mm (range 
0.78 - 2.5 mm), and one death occurred from a melanoma of thickness 2.5mm.  
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Alteration of immunosuppression: Information on immunosuppressive treatment at the time 
of melanoma diagnosis was available in 79/85 (92.9%) cases (supplementary table 2). 
Overall, immunosuppression was altered after a diagnosis of melanoma in 34/79 (43%) 
cases, but the nature of the alteration varied considerably between centres. In all cases 
where dates were given (n=29) immunosuppression was altered within the first year after 
melanoma diagnosis. In 7 centres there were no alterations. Six centres (Austria, Belgium, 
Eire, Netherlands, Lyon, Oxford) performed alteration of immunosuppression in several or all 
of their patients. In 28/34 (82.4%) of cases immunosuppression was reduced but this was 
specifically quantified in only one case as a 50% reduction in dose of prednisolone and 
sirolimus. Of these 34 individuals, one patient (Netherlands, thickness 1.57mm) died from an 
unknown cause 3 years after the reduction in immunosuppression and two patients (Oxford 
4.5mm, Lyon 13mm) died from melanoma at 9 and 10 months post-reduction respectively. In 
four cases (Eire, 2.7mm, 2.98mm; Oxford, 0.3mm; Belgium, 2.5mm) immunosuppression 
was completely withdrawn. In this group one patient (Eire, 2.7mm) died from organ rejection 
and renal failure 8 months after stopping immunosuppression, and another (Belgium, 
2.5mm) died from melanoma within 16 months. In a further 3 cases immunosuppression was 
switched to sirolimus (Austria, MIS; Belgium, 1.2mm; Eire, 1.75mm). All three patients were 
alive at 1.5, 0.4 and 0.3 years follow-up respectively. Overall, there was no significant 
difference in mortality between the groups in whom immunosuppression had been altered or 
not; 3/34 (8.8%) deaths occurred in the former group (2 cases where immunosuppression 
was reduced and one case where it had been stopped) compared with 8/45 (17.8%) in the 
latter (p-value from a Fisher’s exact 0.335).  
 
Ocular Melanomas 
There were two post-transplant ocular melanomas; one uveal melanoma in a 58.1yr old 
female (London, UK) and a choroidal tumour in a 56.9yr old female (Leiden, Netherlands). 
These melanomas were diagnosed 8.1 and 18.9 years post-renal transplant respectively. 
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The patient with the choroidal melanoma was treated with proton beam irradiation and 
infrared thermotherapy but developed liver metastases and died 1.1yrs after diagnosis of the 
melanoma. The patient with uveal melanoma underwent enucleation, and at last follow up, 
1.5yrs post-transplant, was alive with no evidence of recurrence. One choroidal melanoma 
diagnosed 2.3yrs prior to transplantation occurred in a 73.3yr old female renal transplant 
recipient (Leiden, Netherlands) who had been treated with local radiotherapy using 
ruthenium applicator and transpupillary thermotherapy. She was alive and well at 7.7yrs post 
transplant.   
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Discussion 
 
In this study we report outcomes for 9 pre-transplant and 91 post-transplant melanomas in 
95 organ transplant recipients drawn from 14 transplant centres across Europe. Among the 9 
patients in whom a diagnosis of melanoma had been made prior to transplantation, there 
were no melanoma recurrences or melanoma-related deaths. For post transplant cutaneous 
melanoma, five-year survival for T1 and T2 (≤2mm) was similar to that of the AJCC control 
population. However prognosis was significantly worse for post transplant tumours of stage 
T3 or above (p=0.0169). 
 
Pre-transplant melanoma:  
One study to date (5) has systematically examined outcomes for transplant recipients with a 
history of pre-existing melanoma. Penn identified 31 patients, from the Cincinnati Transplant 
Tumour Registry (CTTR) with melanoma prior to transplantation, of whom 6 (19.4%) 
developed recurrent disease and died between 6 and 30 months post transplant (5). 
However, Breslow thickness was not given for any of these melanomas except for one case 
of melanoma-death which was reported as Clarks level IV. Penn recommended that patients 
should wait for at least 5 years after treatment for melanoma before considering solid organ 
transplantation (5), and this seems to be current practise. In our study the mean post-
transplant follow up (60 months; range 0.5-10.2 years) was longer than that of the Penn pre-
transplant melanomas (32 months; range 0.5-100 months). Despite this, we found no 
melanoma recurrences or melanoma-related deaths in the SCOPE cohort. Insufficient 
information was available on the melanomas in the Penn study to make direct comparison, 
however several factors may account for the apparently better outcome in our group. Three 
of nine tumours (30%) were of thickness 1mm (T1) and median time between melanoma 
diagnosis and transplant was 7.8 years (compared to 5.1 years in the Penn group). Recall 
bias in reporting to the CTTR would also tend to favour those pre-transplant melanomas with 
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a poor outcome. Neither our series, nor that of Penn, provides an adequate evidence base 
for reliable recommendation of the interval post-melanoma for which transplantation could be 
considered risk-free. It remains that cases would need to be assessed on an individual 
basis, taking into the account, in addition to all other factors, the predisposition of the patient 
concerned to risk, and the consequences to them of not undertaking transplantation. 
 
Post-transplant cutaneous melanoma: 
Two previous population based studies, one from London and one from Oxford, in the UK, 
found a similar excess risk of 7-8 for post-transplant melanoma compared with the general 
population, but the reported outcomes for the patients were different. In Oxford, only one 
melanoma death was reported in 10 patients (thickness 4.5mm), however all surviving 
patients had T1 melanomas (<1mm thickness) (14). In London, seven cases of melanoma 
were identified in a cohort of OTRs where three of seven (43%) patients died from metastatic 
melanoma; two with Breslow thickness > 2mm and the third with a thickness of just 0.4mm 
(15). Neither of these studies had sufficient power to make comparison with survival figures 
in the general population. 
 
In a third study, data from the  CTTR revealed a 32% mortality among 177 individuals with 
de novo melanoma post-transplantation, compared with overall mortality in our cohort from 
melanoma of 13%. Breslow thickness was available for 42/177 (23.7%) melanomas from the 
CTTR study (5) and of these, 31% were reported to be thin melanomas (<0.76mm) 
compared with 64% (≤,1mm) in our cohort. Again, possible under-reporting of thin 
melanomas to the CTTR could explain the higher mortality in the Penn study, and may well 
reflect reporting bias of thicker tumours to the CTTR.  
 
Our study is thus the first to stratify patients according to a number of AJCC prognostic 
criteria with sufficient power to demonstrate a significantly poorer prognosis for T3 and T4 
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post-transplant tumours compared to the general population (SCOPE group n=12; 
p=0.0169).  
 
Risk Factors: Ultraviolet (UV) light exposure is a recognised factor in the pathogenesis of 
melanoma. Past history of UV exposure is notoriously difficult to quantify, and positive recall 
bias is a well recognised factor in melanoma patients compared with controls. Forty three 
percent of the SCOPE melanoma cohort cited ‘high’ cumulative exposure to UV. Excess 
melanocytic naevi, both benign and dysplastic, have been reported in patients with renal 
allografts compared to controls (23, 24) which may be an independent risk factor for 
melanoma in this group (25, 26). Epidemiological studies in non-transplant patients indicate 
that a prior history of non-melanoma skin cancer is a significant risk factor for melanoma (27, 
28). This holds true for transplant recipients, where we also found a significant association of 
melanoma with both BCC and SCC, supporting a causal role for UV light in the pathogenesis 
of post-transplant melanoma (27, 28).  
 
Clinical and histological features: Post-transplant melanoma was clinically and histologically 
indistinguishable from that seen in the general population. However there was a difference in 
anatomical site; in the general population melanoma demonstrates gender-related site 
predilection, namely melanomas are more common on the legs in females, and the trunk in 
males (29). We did not find this gender predilection in the transplant group, which is in 
keeping with previous reports (5) although sample size may be too small to draw much from 
this. 
 
Management of transplant-associated melanoma: 
Our study indicates a poorer prognosis for those transplant recipients with T3 and T4 
melanomas. This may have bearing on clinical decisions, such as reducing or withdrawing 
immunosuppression in OTRs, with potential sacrifice of the allograft. Expert consensus 
opinion has recently recommended dose reduction or complete withdrawal of 
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immunosuppression in advanced melanoma (30). Of note, despite this recommendation, we 
found no difference in mortality between the group in whom immunosuppression was 
reduced, and those in whom it was not altered (p=0.335). However the data on which our 
analyses are based were limited.  
 
Another option for OTRs with skin cancer is to switch from calcineurin inhibitor (cyclosporine 
or tacrolimus)-based immunosuppression to the mammalian target of rapamycin (mTOR) 
inhibitor sirolimus (rapamycin). The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway 
controls many cellular processes important for development and progression of cancer. 
Sirolimus has anti-angiogenic activities linked to decreased vascular endothelial growth 
factor levels, with inhibition of metastatic tumour growth and angiogenesis in in vivo mouse 
models of melanoma (31).  Retrospective analyses of OTRs treated with sirolimus show 
significantly lower keratinocyte skin cancer rates compared to those treated with calcineurin 
inhibitors (32, 33). Although a number of melanoma patients in the SCOPE cohort were 
switched to sirolimus, the numbers were too small to evaluate effects of this strategy on 
prognosis. Larger studies are now required to establish the potential of sirolimus-induced 
tumour control in OTRs with melanoma. 
 
With improving long-term survival and increasing age at transplantation, melanoma is likely 
to become an increasingly significant problem in the context of organ transplantation. Our 
study suggests that a history of pre-transplant melanoma should not necessarily preclude 
subsequent organ transplantation, particularly for thin (T1 and T2) melanomas. This is also 
the first study with sufficient power to comment on prognosis for melanoma post transplant; 
stage T1 and T2 post-transplant melanomas (≤2mm) appear to have similar outcomes to 
corresponding stage melanomas in the general population, whereas prognosis is 
significantly worse for individuals with post transplant T3 and T4 melanomas. Further studies 
should be designed to examine the effect of withdrawal or reduction of immunosuppression 
in this situation but, given the current lack of effective treatments for advanced melanoma, 
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regular skin surveillance with a view to early curative surgical intervention is likely to have 
greatest impact of mortality in coming years. Evidence suggests that dedicated transplant 
dermatology clinics are the most effective means of attaining this goal (34).  
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Table 1: Melanoma cases included from participating centres. 
 
 
Centre Post-transplant 
melanomas (n=91) 
Pre-transplant melanomas 
(n=9) 
Vienna, Austria 5  
Brussels, Belgium 5 1 
Berlin, Germany 6 2 
Dublin, Ireland 5 1 
Padova, Italy 4  
Leiden, Netherlands 9 ( + 1 ocular) 1 ( + 1 ocular) 
London, UK 10 (+ 1 ocular)  
Lyon, France 9 3 
Manchester, UK 3  
Oxford, UK 24  
Paris, France 3  
Barcelona, Spain 2  
Zurich, Switzerland 4  
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Table 2: Clinical features of patients with post-transplant melanoma 
  
 Number (%) of patients  
Transplanted organ (n=85)  
Kidney 71 (84) 
Heart 8 (9) 
Liver 3 (4) 
Renal and pancreas 2 (2) 
Lung 1 (1)   
Number of transplants per patient (n=85)  
1 69 (81.2) 
2 13 (15.3) 
3 2 (2.4) 
4 1 (1.1) 
Number of moles (n=77)  
None 16 (20.8) 
1-50 16 (20.8) 
51-100 42 (54.5) 
>100 3 (3.9) 
Presence of atypical moles (n=63)  
Yes 23 (37) 
No 40 (63) 
Atypical mole syndrome (n=64)^  
Yes 12 (19) 
No 52 (81) 
Origin of melanoma in a pre-existing naevus
(n=69) 
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Yes 26 (38) 
No 43 (62) 
Skin phototypes (n=76)*  
I 17 (22) 
II 29 (38) 
III 26 (34) 
IV 2 (3) 
V 2 (3) 
Sun exposure history# (n=58)  
LOW 19 (33) 
INTERMEDIATE 14 (24) 
HIGH  25 (43) 
 
^ Fulfils atypical mole syndrome criteria: 100 or more naevi >2mm (50 or more if under 20y 
or over 50y of age), 2 or more atypical moles, 1 or more naevi on buttocks, 2 or more naevi 
on dorsum of feet: total score 2 or more features. 
 
*Fitzpatrick skin types: I: always burns/never tans; II: usually burns/sometimes tans; III: 
usually tans/sometimes burns; IV: always tans/rarely burns; V: Asian; VI: Black African and 
Afro-Caribbean. 
 
# High UV-exposure equates to an outdoor occupation for >5 years; or living in a sunny 
climate for >6 months; or a ‘sun worshipper’ who actively seeks a suntan for >2 weeks per 
year for >10 years. Low UV-exposure equates to an indoor occupation; hasn’t lived in a 
sunny climate; avoids the sun/doesn’t sunbathe etc. Intermediate UV-exposure falls between 
the ‘high’ and ‘low’ categories.  
 
 27
Table 3: Anatomical distribution of post-transplant cutaneous melanoma according to 
histological subtype* 
 
 TIS 
Male 
(Female) 
LMM 
Male 
(Female) 
SSM 
Male 
(Female)
NMM 
Male 
(Female)
Unknown
Male 
(Female) 
Total 
Male (Female) 
Head/Neck 7 (1) (1) 4 (1) 5 2 (2) 18 (5) 
Trunk 9 (3) 2 12 (4) 5 1 (2) 29 (9) 
Upper limbs 1 (2) 1 3 (3) 1 (1)  6 (6) 
Lower limbs   6 (6)  2 8 (6) 
      61 (26)# 
  
* LMM – lentigo maligna melanoma; SSM – superficial spreading melanoma; NMM – nodular 
malignant melanoma. 
 
# In 2 cases site was unknown  
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Table 4: Histopathological characteristics of post-transplant cutaneous melanomas 
 
 Number 
(percentage) of 
melanomas  
Histological subtype* 
(n=81) 
 
SSM 40 (49) 
NMM 12 (15) 
LMM 4 (5) 
In situ 23 (28) 
Metastases 2 (3) 
Breslow thickness (n=83)  
In situ 23 (28) 
0.01 - 1mm 38 (46) 
1.01 – 2mm 9 (11) 
2.01 – 4mm 7 (8) 
>4mm 6 (7) 
Clarks Level (n=82)#  
I 23 (28) 
II 15 (18) 
III 24 (29) 
IV 18 (22) 
V 2 (3) 
Growth phase (n=49)  
Radial 22 (45) 
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Vertical 27 (55) 
Ulceration (n=79)  
Present 12 (15) 
Absent 67 (85) 
Regression (n=59)  
Present 13 (22) 
Absent 46 (78) 
 
* In situ – melanoma in situ (TIS); LMM – lentigo maligna melanoma; SSM – superficial 
spreading melanoma; NMM – nodular malignant melanoma. 
 
# Clarks Level: Invasion of melanoma limited to the epidermis (I); into the underlying 
papillary dermis, (II); to the junction of the papillary and reticular dermis, (III); into the 
reticular dermis, (IV); into the subcutaneous fat, (V). 
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Table 5: Outcome data for SCOPE cohort and AJCC-matched cohort (Balch 2001) 
 
 SCOPE data 
(n=53) 
Mean ± SD or N (%) 
AJCC-matched data 
(n=212) 
Mean ± SD or N (%) 
Age 
 
52.9 ± 12.0 52.9 ± 12.7 
Sex 
  Female 
  Male 
 
 
16 (30.2) 
37 (69.8) 
 
  64 (30.2) 
148 (69.8) 
Tumor thickness 
  <1.0 
  1.01-2.0 
  2.01-4.0 
  >4.0 
 
 
34 (64.2) 
  7 (13.2) 
  7 (13.2) 
  5 (  9.4) 
 
136 (64.2) 
  28 (13.2) 
  28 (13.2) 
  20 (  9.4) 
Ulceration  
  No  
  Yes 
 
 
43 (81.1) 
10 (18.9) 
 
172 (81.1) 
  40 (18.9) 
Death due to melanoma 
  No 
  Yes 
 
45 (84.9) 
  8 (15.1) 
 
194 (91.5) 
  18 (  8.5) 
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Supplementary table 1: Site and management of metastatic melanoma 
 
 Number (%) of cases
Site of metastases 
(Total n=14) 
 
Cutaneous 4 (29) 
Bladder 2 (14) 
Bone 4 (29) 
Brain 3 (21) 
Liver 4 (29) 
Lung 2 (14) 
Lymph nodes 9 (64) 
  
Treatment of metastases  
Bevacizumab 1 (7) 
CO2 laser 1 (7) 
Dacarbazine 3 (21) 
Fotemustine 1 (7) 
Lymph node dissection 8 (57) 
Radiotherapy 3 (21) 
Temozolomide 1 (7) 
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Supplementary Table 2: Immunosuppressant treatment of post-transplant melanoma 
 
Immunosuppressant(s) 
(n=79) 
Number (%) of cases 
Prednisolone 64 (81) 
Azathioprine 43 (54) 
Cyclosporin 57 (72) 
Mycophenolate mofetil 17 (22) 
Tacrolimus 9 (11) 
Rapamycin 2 (3) 
Everolimus 1 (1) 
  
COMBINATIONS #  
Prednisolone / Azathioprine / Cyclosporin 20 (25) 
Prednisolone / Cyclosporin 14 (18) 
Prednisolone / Azathioprine 11 (14) 
Azathioprine / Cyclosporin 10 (13) 
Prednisolone / Mycophenolate Mofetil / Cyclosporin 8 (10) 
Prednisolone / Mycophenolate Mofetil / Tacrolimus 5 (6) 
Cyclosporin / Mycophenolate Mofetil 2 (3) 
Prednisolone / Azathioprine /Tacrolimus 2 (3) 
 
# In addition there was one case being prescribed each of the following combinations: 
Prednisolone / Cyclosporin / Tacrolimus, Prednisolone / Rapamycin, Tacrolimus alone, 
Cyclosporin alone, Mycophenolate Mofetil / Rapamycin, Prednisolone / Mycophenolate 
Mofetil, Prednisolone / Cyclosporin / Everolimus 
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Table 6: Clinical and histological data for pre-transplant melanomas. 
 
 
 
 
 
 
 
 
 
#NMM – nodular malignant melanoma, ALM – acral lentiginous melanoma, SSM – superficial spreading melanoma  
NA – data not available 
 
*Patient had a further melanoma on the trunk 3.1yrs post transplant  
 Gender / 
Age at 
transplant 
(yrs) 
Organ 
transplanted 
Age at 
melanoma 
diagnosis  
(yrs) 
Interval from 
melanoma 
diagnosis to 
transplant 
(yrs) 
Site of 
melanoma  
Skin type  Histological 
type # 
Breslow 
thickness 
(mm) 
Post 
transplant 
f/up (yrs) 
Outcome 
1 F / 57.7 Renal 52.2 5.5 Leg II  NMM 1 1.8 Alive 
2 F / 76.5 Renal 63.6 13.0 Foot I  ALM NA 5.5 Alive 
3 F / 35.2 Renal 34.8 0.4 Leg II  0.63 2.9 Alive 
4 F / 46.8 Renal + 
Pancreas 
43.4 3.3 Leg NA  NMM 2.2 6.0 Alive 
5 F / 57.8 Renal 25.2 32.5 Leg III   NA 9.4 Alive* 
6 M / 64.0 Heart 51.0 13.0 Buttock III   18 3.4 Alive 
7 F / 46.7 Renal 38.9 7.8 Hand III  ALM 1.24 10.2 Alive 
8 M / 63.5  Heart and 
Lung 
50.4 13.2 Trunk NA SSM 0.5 0.5 Alive 
9 F / 75.6 Renal 73.3 2.3 Choroid NA Ocular NA 7.7 Alive 
Figure 1: Kaplan Meier Survival Curves for T1 and T2 melanomas (thickness ≤ 2mm)
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Figure 2: Kaplan Meier Survival Curves for T3 and T4 melanomas (thickness >2mm)
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